RxDoctor Payments Data

Ryan Lee, PA

Physician Assistant · Columbia, SCNPI 1932570470

Payments from drug & device makers

$5,081in general payments, 2019–2025

Across 211 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$420
  • Pfizer$416
  • Urogen Pharma, Inc.$347
  • Dendreon Pharmaceuticals LLC$346
  • Sumitomo Pharma America, Inc.$256
  • Teleflex LLC$182
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,081 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$240,473
Medicare patients
1,540
Services billed
8,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron139$134,872
MyrbetriqMirabegron104$89,825
XyostedTestosterone Enanthate39$43,890
Testosterone Cypionate330$14,712
Testosterone53$12,286
Tamsulosin Hcl559$8,889
Estradiol72$4,755
Potassium Citrate ErPotassium Citrate34$4,392
Solifenacin Succinate66$3,833
Finasteride150$2,084
Tadalafil19$1,829
Methenamine Hippurate14$1,386
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$1,036
NitrofurantoinNitrofurantoin Macrocrystal17$842
Alfuzosin Hcl ErAlfuzosin Hcl18$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$256$134,872139 claims
Astellas Pharma US IncMyrbetriq$69$89,825104 claims
Antares Pharma, Inc.Xyosted$420$43,89039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →